syahrir maulana Sana Biotechnology ( NASDAQ: SANA ) said it was suspending two drug development programs and will instead focus its resources on developing its drug candidates for type 1 diabetes and b-cell mediated autoimmune diseases. The two programs to be suspended are SC291 in.
Back to Health Page
